- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of enterprise cheminformatics software, announced the addition of Pfizer to the Accelrys Enterprise Cheminformatics Consortium ("Consortium"). The Consortium will be a collaborative software development project led by Accelrys in partnership with a group of commercial member organizations. Its goal is to prioritize, design, and develop enterprise cheminformatics software components and services to allow members to implement industry-leading cheminformatics systems. The Consortium will commence in early 2007 and have a three year duration.
"Close partnership and collaboration with industry is essential for Accelrys to develop software and services that help solve critical research problems," said Mark J. Emkjer, president and chief executive officer of Accelrys. "We are delighted to have Pfizer join the consortium as our inaugural member and believe it will be instrumental in helping to guide the development of our next generation cheminformatics solutions that will address current and burgeoning research and development process and business challenges."
This latest consortium initiative in the enterprise cheminformatics area will be an extension of the successful Accelrys consortium model, which in previous consortia has delivered important scientific advancements in areas such as catalysis, combinatorial chemistry, and nanotechnology. The consortium model is a customer-centric approach to better understand development needs. Consortium members collaborate in directing research and development activities that will result in products and services that solve important business issues and, accordingly, members will secure a period of exclusivity on the resulting consortium deliverables.
Accelrys provides scientific innovation and technology leadership in delivering software and service solutions that span the continuum of discovery and development research. A unique combination of expertise in life and materials science, informatics, and scientific operating platform technologies, lets Accelrys serve a diverse range of clients, including some of the world’s leading pharmaceutical, biotechnology, chemical, and nanotechnology research organizations. Accelrys is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/ .
Statements contained in this press release relating to the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. Such forward-looking statements, including but not limited to statements relating to the formation and future success of the consortium, release and demand for products and services resulting therefrom, are subject to a number of risks and uncertainties, including risks that the Consortium will not be successfully launched and that products and services will not be successfully developed therein, risks related to the demand for such products and services, as well as the risks and uncertainties that are contained from time to time in the Company's SEC filings, including but not limited to the Company's Annual Report on Form 10-K for the year ended March 31, 2006, quarterly reports on Form 10-Q and current reports on Form 8-K. The Company's actual results could differ materially from those projected in such forward-looking statements due to these risks and uncertainties, and the Company disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future events or otherwise.
For more information, please click here
Philomena Walsh, 858-799-5440
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
A nano-roundabout for light December 10th, 2016
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016